JP2006506613A - 抗体または好中球を介するオゾン生成 - Google Patents

抗体または好中球を介するオゾン生成 Download PDF

Info

Publication number
JP2006506613A
JP2006506613A JP2004551020A JP2004551020A JP2006506613A JP 2006506613 A JP2006506613 A JP 2006506613A JP 2004551020 A JP2004551020 A JP 2004551020A JP 2004551020 A JP2004551020 A JP 2004551020A JP 2006506613 A JP2006506613 A JP 2006506613A
Authority
JP
Japan
Prior art keywords
antibody
oxygen species
reactive oxygen
sample
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004551020A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506613A5 (enExample
Inventor
ポール・ウェントワース
リチャード・エイ・ラーナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of JP2006506613A publication Critical patent/JP2006506613A/ja
Publication of JP2006506613A5 publication Critical patent/JP2006506613A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2004551020A 2002-11-14 2003-11-13 抗体または好中球を介するオゾン生成 Pending JP2006506613A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42624502P 2002-11-14 2002-11-14
PCT/EP2003/012710 WO2004044582A2 (en) 2002-11-14 2003-11-13 Antibody- or neutrophil-mediated ozone generation

Publications (2)

Publication Number Publication Date
JP2006506613A true JP2006506613A (ja) 2006-02-23
JP2006506613A5 JP2006506613A5 (enExample) 2006-12-28

Family

ID=32313124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004551020A Pending JP2006506613A (ja) 2002-11-14 2003-11-13 抗体または好中球を介するオゾン生成

Country Status (8)

Country Link
US (1) US20060292076A1 (enExample)
EP (1) EP1563299A2 (enExample)
JP (1) JP2006506613A (enExample)
CN (1) CN100570365C (enExample)
AU (1) AU2003288058A1 (enExample)
BR (1) BR0315628A (enExample)
CA (1) CA2505923A1 (enExample)
WO (1) WO2004044582A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009128240A (ja) * 2007-11-26 2009-06-11 Shimadzu Corp タンパク質試料中のメチオニン残基の酸化状態を解析する方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684521A (en) * 1982-12-08 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5162217A (en) * 1984-08-27 1992-11-10 Bio-Technology General Corp. Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda PL promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof
US6030611A (en) * 1984-08-27 2000-02-29 Bio-Technology General Corp. Therapeutic SOD compositions and uses thereof
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
DE3619436A1 (de) * 1986-06-10 1987-12-17 Bayer Ag Triaryl- und trihetarylmethanderivate als redoxindikatoren und deren verwendung
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
DE4038563A1 (de) * 1990-12-04 1992-06-11 Gruenenthal Gmbh Verwendung von superoxiddismutasen zur prophylaxe und/oder behandlung von organversagen bei risikopatienten mit polytrauma
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US5599712A (en) * 1993-10-15 1997-02-04 University Of Pittsburgh Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
US5647315A (en) * 1994-10-07 1997-07-15 Yamaha Hatsudoki Kabushiki Kaisha Lubricating arrangement for engine
JPH08249306A (ja) * 1995-03-09 1996-09-27 Sharp Corp データ駆動型情報処理装置
US6822070B2 (en) * 1996-03-11 2004-11-23 David Baltimore Truncated CRAF1 inhibits CD40 signaling
AU2394597A (en) * 1996-04-18 1997-11-07 Medical Research Council Oxidative metabolism in smooth muscle cells: methods and materials relating thereto
GB9621440D0 (en) * 1996-10-15 1996-12-04 Renold Plc A chain tensioner
GB9622159D0 (en) * 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
US6040611A (en) * 1998-09-10 2000-03-21 Hughes Electonics Corporation Microelectromechanical device
EP1153010A1 (en) * 1999-02-08 2001-11-14 Checkpoint Genetics, Inc. $i(N)-SUBSTITUTED AMINO ACIDS, ANTIOXIDANT PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS USING SAME

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JPN6009032818, Ｌｉｆｅ Ｓｃｉ, 1988, Ｖｏｌ．４３， Ｎｏ．１１, Ｐａｇｅ．９２３−９２８ *
JPN6009032820, Ｊ Ｂｉｏｃｈｅｍ, 2000, Ｖｏｌ．１２７， Ｎｏ．６, Ｐａｇｅ．９７１−９７６ *
JPN6009032823, Ｊ Ｉｍｍｕｎｏｌ, 1983, Ｖｏｌ．１３０， Ｎｏ．４, Ｐａｇｅ．１９１０−１９１７ *
JPN6009032826, Ｐｈｙｔｏｔｈｅｒ Ｒｅｓ, 2002, Ｖｏｌ．１６, Ｐａｇｅ．５２４−５２８ *
JPN6009032829, Ａｒｚｎｅｉｍ Ｆｏｒｓｃｈ, 1991, Ｖｏｌ．４１， Ｎｏ．５, Ｐａｇｅ．４６９−４７４ *
JPN6009032831, Ｐｒｏｃ Ｎａｔｌ Ａｃａｄ Ｓｃｉ ＵＳＡ, 2003, Ｖｏｌ．１００， Ｎｏ．６, Ｐａｇｅ．３０３１−３０３４ *
JPN6010002643, Ｉｎｆｒａｍｍ Ｒｅｓ, 1996, Ｖｏｌ．４５， Ｎｏ．７, Ｐａｇｅ．３１３−３１５ *
JPN6010002647, Ａｎａｌ Ｂｉｏｃｈｅｍ, 1987, Ｖｏｌ．１６０， Ｎｏ．１, Ｐａｇｅ．１３９−１４８ *
JPN6010002651, Ｈｕｍ Ｃｅｌｌ, 1993, Ｖｏｌ．６， Ｎｏ．４, Ｐａｇｅ．２４５−２５２ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009128240A (ja) * 2007-11-26 2009-06-11 Shimadzu Corp タンパク質試料中のメチオニン残基の酸化状態を解析する方法

Also Published As

Publication number Publication date
CN100570365C (zh) 2009-12-16
EP1563299A2 (en) 2005-08-17
WO2004044582A2 (en) 2004-05-27
BR0315628A (pt) 2005-08-23
AU2003288058A1 (en) 2004-06-03
WO2004044582A3 (en) 2004-09-16
US20060292076A1 (en) 2006-12-28
CN1739028A (zh) 2006-02-22
AU2003288058A8 (en) 2004-06-03
CA2505923A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
Ding et al. Size-dependent toxicity of polystyrene microplastics on the gastrointestinal tract: Oxidative stress related-DNA damage and potential carcinogenicity
Chen et al. BRD4770 functions as a novel ferroptosis inhibitor to protect against aortic dissection
Ye et al. SIRT3 activator honokiol ameliorates surgery/anesthesia‐induced cognitive decline in mice through anti‐oxidative stress and anti‐inflammatory in hippocampus
Buonfiglio et al. Oxidative stress: a suitable therapeutic target for optic nerve diseases?
Guo et al. Irisin Rescues Blood‐Brain Barrier Permeability Following Traumatic Brain Injury and Contributes to the Neuroprotection of Exercise in Traumatic Brain Injury
Von Bernhardi et al. Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms
Horan et al. Association of neutrophil chemiluminescence with microbicidal activity
Lin et al. β‐Sitosterol Protects against Myocardial Ischemia/Reperfusion Injury via Targeting PPARγ/NF‐κB Signalling
Muhlestein et al. Chronic infection and coronary artery disease
US20050025734A1 (en) Inhibitors of proteasomal activity for stimulating hair growth
Singh et al. Microglial inhibitory mechanism of coenzyme Q10 against Aβ (1-42) induced cognitive dysfunctions: possible behavioral, biochemical, cellular, and histopathological alterations
Zhao et al. Marine compound Xyloketal B protects PC12 cells against OGD-induced cell damage
Blasi et al. Variants of Porphyromonas gingivalis lipopolysaccharide alter lipidation of autophagic protein, microtubule‐associated protein 1 light chain 3, LC3
AU2002212970B2 (en) Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
Chen et al. Streptococcus lutetiensis induces autophagy via oxidative stress in bovine mammary epithelial cells
AU2002212970A1 (en) Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
Yao et al. The role of potential oxidative biomarkers in the prognosis of intracerebral hemorrhage and the exploration antioxidants as possible preventive and treatment options
Ellis et al. Cellular localization and enzymatic activity of cathepsin B after spinal cord injury in the rat
Tousson et al. Renal protective effect of ginkgo biloba and l-carnitine extracts against pentylenetetrazol induced toxicity, oxidative stress, injury and proliferation alternation in epileptic rats
US20070009537A1 (en) Antimicrobial activity of antibodies producing reactive oxygen species
US20050129680A1 (en) Antimicrobial activity of antibodies
Omar et al. Metformin versus silymarin as hepatoprotective agents in mice fibrotic model caused by carbon tetrachloride
US20040157280A1 (en) Antibody mediated ozone generation
Ullah et al. Andrographolide Promotes Ferroptosis in Pancreatic Cancer via Targeting and Activating HSP90/GPX4 Ubiquitination
US20060292076A1 (en) Antimicrobial mediated ozone generation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061110

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100803